Interventional heart failure management is emerging as a new and promising frontier in cardiovascular medicine, offering hope to patients with few effective treatment options. Among the innovators leading this transformation is Gradient Denervation Technologies, whose novel approach to pulmonary artery denervation has the potential to significantly improve outcomes for patients with pulmonary hypertension secondary to left heart disease.
Gradient Denervation Technologies, a Paris-based leader in cardiovascular innovation, has developed a minimally invasive, ultrasound-based system designed to target the nerves surrounding the pulmonary artery. By reducing sympathetic nervous system activity, this technology may help lower vascular resistance and pulmonary artery pressures—addressing a critical unmet need in this complex patient population.
We are pleased to see Gradient’s continued progress, following a strong and successful launch of their clinical program with the first-in-human (FIH) study conducted by Clinical Accelerator in Georgia. It has been an honor to support this initiative from its earliest stages, and we remain deeply committed to advancing pioneering therapies through trusted, strategic collaborations.
We also extend our sincere gratitude to Dr. Alex Rothman for his invaluable guidance and support to the Georgian clinical team throughout the execution of Gradient’s FIH study. We look forward to the continued advancement and success of this vital clinical program.